Environment and primary biliary cirrhosis: Electrophilic drugs and the induction of AMA

Journal of Autoimmunity

Volumn 41, Issue , 2013, Pages 79-86

  Leung, Patrick S C ^a   Wang, Jinjun ^a   Naiyanetr, Phornnop ^a,b   Kenny, Thomas P ^a   Lam, Kit S ^c   Kurth, Mark J ^a   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimitochondrial antibodies; Environment; Primary biliary cirrhosis

Indexed keywords

ANTIGEN; ARANIDIPINE; IMMUNOGLOBULIN CLASS; MITOCHONDRION ANTIBODY; N ACETYL 1,4 BENZOQUINONE IMINE; PARACETAMOL; THIOCTIC ACID; XENOBIOTIC AGENT;

ACUTE LIVER FAILURE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; AUTOIMMUNITY; DISULFIDE BOND; ELECTROPHILICITY; ENVIRONMENTAL FACTOR; HUMAN; IMMUNOBIOLOGY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; LIVER INJURY; MOLECULAR MIMICRY; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PRIMARY BILIARY CIRRHOSIS; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN MODIFICATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RHEUMATOID ARTHRITIS; SCLEROSIS; SECONDARY IMMUNE RESPONSE; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; AUTOANTIBODIES; BINDING SITES; EPITOPES; HUMANS; LIVER CIRRHOSIS, BILIARY; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN SUBUNITS; PYRUVATE DEHYDROGENASE COMPLEX; THIOCTIC ACID; XENOBIOTICS;

EID: 84875923455     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.12.007     Document Type: Article

References (80)

1. Miller F.W., Alfredsson L., Costenbader K.H., Kamen D.L., Nelson L.M., Norris J.M., et al. Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. Journal of Autoimmunity 2012, 39:259-271.
2. Miller F.W., Pollard K.M., Parks C.G., Germolec D.R., Leung P.S., Selmi C., et al. Criteria for environmentally associated autoimmune diseases. Journal of Autoimmunity 2012, 39:253-258.
3. Selmi C., Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., et al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences Expert Panel Workshop. Journal of Autoimmunity 2012, 39:272-284.
4. Carter C.J. Epstein-Barr and other viral mimicry of autoantigens, myelin and vitamin D-related proteins and of EIF2B, the cause of vanishing white matter disease: massive mimicry of multiple sclerosis relevant proteins by the Synechococcus phage. Immunopharmacology and Immunotoxicology 2012, 34:21-35.
5. Ebringer A., Rashid T., Wilson C. The role of Acinetobacter in the pathogenesis of multiple sclerosis examined by using Popper sequences. Medical Hypotheses 2012, 78:763-769.
6. McCarthy D.P., Richards M.H., Miller S.D. Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease. Methods in Molecular Biology 2012, 900:381-401.
7. James J.A., Robertson J.M. Lupus and Epstein-Barr. Current Opinion in Rheumatology 2012, 24:383-388.
8. Poole B.D., Scofield R.H., Harley J.B., James J.A. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006, 39:63-70.
9. Babu Chodisetti S., Rai P.K., Gowthaman U., Pahari S., Agrewala J.N. Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis. BMC Immunology 2012, 13:13.
10. Rashid T., Ebringer A. Autoimmunity in rheumatic diseases is induced by microbial infections via crossreactivity or molecular mimicry. Autoimmune Diseases 2012, 2012:539282.
11. van Eden W., Hogervorst E.J., Hensen E.J., van der Zee R., van Embden J.D., Cohen I.R. A cartilage-mimicking T-cell epitope on a 65K mycobacterial heat-shock protein: adjuvant arthritis as a model for human rheumatoid arthritis. Current Topics in Microbiology and Immunology 1989, 145:27-43.
12. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. The New England Journal of Medicine 2002, 347:911-920.
13. Christen U., Quinn J., Yeaman S.J., Kenna J.G., Clarke J.B., Gandolfi A.J., et al. Identification of the dihydrolipoamide acetyltransferase subunit of the human pyruvate dehydrogenase complex as an autoantigen in halothane hepatitis. Molecular mimicry of trifluoroacetyl-lysine by lipoic acid. European Journal of Biochemistry 1994, 223:1035-1047.
14. Kim W.R., Lindor K.D., Locke G.R., Therneau T.M., Homburger H.A., Batts K.P., et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000, 119:1631-1636.
15. Myers R.P., Shaheen A.A., Fong A., Burak K.W., Wan A., Swain M.G., et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology 2009, 50:1884-1892.
16. Rautiainen H., Salomaa V., Niemela S., Karvonen A.L., Nurmi H., Isoniemi H., et al. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scandinavian Journal of Gastroenterology 2007, 42:1347-1353.
17. Farrell G.C. Primary biliary cirrhosis in Asians: less common than in Europeans, but just as depressing. Journal of Gastroenterology and Hepatology 2008, 23:508-511.
18. Invernizzi P. Geoepidemiology of autoimmune liver diseases. Journal of Autoimmunity 2010, 34:J300-J306.
19. Gershwin M.E., Mackay I.R. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 2008, 47:737-745.
20. Benson G.D., Kikuchi K., Miyakawa H., Tanaka A., Watnik M.R., Gershwin M.E. Serial analysis of antimitochondrial antibody in patients with primary biliary cirrhosis. Clinical and Developmental Immunology 2004, 11:129-133.
21. Mayo M.J. Natural history of primary biliary cirrhosis. Clinics in Liver Disease 2008, 12:277-288. [viii].
22. Prince M.I., Chetwynd A., Craig W.L., Metcalf J.V., James O.F. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004, 53:865-870.
23. Invernizzi P., Miozzo M., Battezzati P.M., Bianchi I., Grati F.R., Simoni G., et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004, 363:533-535.
24. Liu X., Invernizzi P., Lu Y., Kosoy R., Bianchi I., Podda M., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics 2010, 42:658-660.
25. Mells G.F., Floyd J.A., Morley K.I., Cordell H.J., Franklin C.S., Shin S.Y., et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nature Genetics 2011, 43:329-332.
26. Hirschfield G.M., Liu X., Han Y., Gorlov I.P., Lu Y., Xu C., et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nature Genetics 2010, 42:655-657.
27. Hirschfield G.M., Liu X., Xu C., Lu Y., Xie G., Gu X., et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. The New England Journal of Medicine 2009, 360:2544-2555.
28. Bach N., Schaffner F. Familial primary biliary cirrhosis. Journal of Hepatology 1994, 20:698-701.
29. Lazaridis K.N., Juran B.D., Boe G.M., Slusser J.P., de Andrade M., Homburger H.A., et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007, 46:785-792.
30. Selmi C., Mayo M.J., Bach N., Ishibashi H., Invernizzi P., Gish R.G., et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004, 127:485-492.
31. Smyk D., Cholongitas E., Kriese S., Rigopoulou E.I., Bogdanos D.P. Primary biliary cirrhosis: family stories. Autoimmune Diseases 2011, 2011:189585.
32. Ala A., Stanca C.M., Bu-Ghanim M., Ahmado I., Branch A.D., Schiano T.D., et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 2006, 43:525-531.
33. Amano K., Leung P.S., Rieger R., Quan C., Wang X., Marik J., et al. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. Journal of Immunology 2005, 174:5874-5883.
34. Selmi C., Balkwill D.L., Invernizzi P., Ansari A.A., Coppel R.L., Podda M., et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003, 38:1250-1257.
35. Ngalamika O., Zhang Y., Yin H., Zhao M., Gershwin M.E., Lu Q. Epigenetics, autoimmunity and hematologic malignancies: a comprehensive review. Journal of Autoimmunity 2012, 39:451-465.
36. Greer J.M., McCombe P.A. The role of epigenetic mechanisms and processes in autoimmune disorders. Biologics: Targets and Therapy 2012, 6:307-327.
37. Selmi C., Lu Q., Humble M.C. Heritability versus the role of the environment in autoimmunity. Journal of Autoimmunity 2012, 39:249-252.
38. Zenewicz L.A., Abraham C., Flavell R.A., Cho J.H. Unraveling the genetics of autoimmunity. Cell 2010, 140:791-797.
39. Bogdanos D.P., Smyk D.S., Rigopoulou E.I., Mytilinaiou M.G., Heneghan M.A., Selmi C., et al. Twin studies in autoimmune disease: genetics, gender and environment. Journal of Autoimmunity 2012, 38:J156-J169.
40. Moroni L., Bianchi I., Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmunity Reviews 2012, 11:A386-A392.
41. Pollard K.M. Gender differences in autoimmunity associated with exposure to environmental factors. Journal of Autoimmunity 2012, 38:J177-J186.
42. Germolec D., Kono D.H., Pfau J.C., Pollard K.M. Animal models used to examine the role of the environment in the development of autoimmune disease: findings from an NIEHS Expert Panel Workshop. Journal of Autoimmunity 2012, 39:285-293.
43. Oertelt S., Rieger R., Selmi C., Invernizzi P., Ansari A.A., Coppel R.L., et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007, 45:659-665.
44. Gershwin M.E., Mackay I.R., Sturgess A., Coppel R.L. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. Journal of Immunology 1987, 138:3525-3531.
45. Leung P.S., Chuang D.T., Wynn R.M., Cha S., Danner D.J., Ansari A., et al. Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope. Hepatology 1995, 22:505-513.
46. Moteki S., Leung P.S., Dickson E.R., Van Thiel D.H., Galperin C., Buch T., et al. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology 1996, 23:436-444.
47. Van de Water J., Gershwin M.E., Leung P., Ansari A., Coppel R.L. The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase. The Journal of Experimental Medicine 1988, 167:1791-1799.
48. Dubel L., Tanaka A., Leung P.S., Van de Water J., Coppel R., Roche T., et al. Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis. Hepatology 1999, 29:1013-1018.
49. Mao T.K., Davis P.A., Odin J.A., Coppel R.L., Gershwin M.E. Sidechain biology and the immunogenicity of PDC-E2, the major autoantigen of primary biliary cirrhosis. Hepatology 2004, 40:1241-1248.
50. Moteki S., Leung P.S., Coppel R.L., Dickson E.R., Kaplan M.M., Munoz S., et al. Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Hepatology 1996, 24:97-103.
51. Liu H., Norman G.L., Shums Z., Worman H.J., Krawitt E.L., Bizzaro N., et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. Journal of Autoimmunity 2010, 35:436-442.
52. Shimoda S., Van de Water J., Ansari A., Nakamura M., Ishibashi H., Coppel R.L., et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. The Journal of Clinical Investigation 1998, 102:1831-1840.
53. Matsumura S., Kita H., He X.S., Ansari A.A., Lian Z.X., Van De Water J., et al. Comprehensive mapping of HLA-A0201-restricted CD8 T-cell epitopes on PDC-E2 in primary biliary cirrhosis. Hepatology 2002, 36:1125-1134.
54. Mao T.K., Lian Z.X., Selmi C., Ichiki Y., Ashwood P., Ansari A.A., et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 2005, 42:802-808.
55. Moritoki Y., Lian Z.X., Wulff H., Yang G.X., Chuang Y.H., Lan R.Y., et al. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology 2007, 45:314-322.
56. Shimoda S., Miyakawa H., Nakamura M., Ishibashi H., Kikuchi K., Kita H., et al. CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. Journal of Autoimmunity 2008, 31:110-115.
57. Shimoda S., Harada K., Niiro H., Shirabe K., Taketomi A., Maehara Y., et al. Interaction between toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 2011, 53:1270-1281.
58. Howard M.J., Fuller C., Broadhurst R.W., Perham R.N., Tang J.G., Quinn J., et al. Three-dimensional structure of the major autoantigen in primary biliary cirrhosis. Gastroenterology 1998, 115:139-146.
59. Jones D.D., Stott K.M., Howard M.J., Perham R.N. Restricted motion of the lipoyl-lysine swinging arm in the pyruvate dehydrogenase complex of Escherichia coli. Biochemistry 2000, 39:8448-8459.
60. Vijayakrishnan S., Kelly S.M., Gilbert R.J., Callow P., Bhella D., Forsyth T., et al. Solution structure and characterisation of the human pyruvate dehydrogenase complex core assembly. Journal of Molecular Biology 2010, 399:71-93.
61. Bruggraber S.F., Leung P.S., Amano K., Quan C., Kurth M.J., Nantz M.H., et al. Autoreactivity to lipoate and a conjugated form of lipoate in primary biliary cirrhosis. Gastroenterology 2003, 125:1705-1713.
62. Naiyanetr P., Butler J.D., Meng L., Pfeiff J., Kenny T.P., Guggenheim K.G., et al. Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity. Journal of Autoimmunity 2011, 37:209-216.
63. Rieger R., Leung P.S., Jeddeloh M.R., Kurth M.J., Nantz M.H., Lam K.S., et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. Journal of Autoimmunity 2006, 27:7-16.
64. Odin J.A., Huebert R.C., Casciola-Rosen L., LaRusso N.F., Rosen A. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. The Journal of Clinical Investigation 2001, 108:223-232.
65. Mendel-Hartvig I., Nelson B.D., Loof L., Totterman T.H. Primary biliary cirrhosis: further biochemical and immunological characterization of mitochondrial antigens. Clinical and Experimental Immunology 1985, 62:371-379.
66. Chen R.C.Y., Naiyanetr P., Shu S.-A., Wang J., Yang G.-X., Kenny T.P., et al. AMA heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology 2012, http://dx.doi.org/10.1002/hep.26157.
67. Sevior D.K., Pelkonen O., Ahokas J.T. Hepatocytes: the powerhouse of biotransformation. The International Journal of Biochemistry and Cell Biology 2012, 44:257-261.
68. Gu X., Manautou J.E. Molecular mechanisms underlying chemical liver injury. Expert Reviews in Molecular Medicine 2012, 14:e4.
69. Leung P.S., Rossaro L., Davis P.A., Park O., Tanaka A., Kikuchi K., et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 2007, 46:1436-1442.
70. Ferret P.J., Hammoud R., Tulliez M., Tran A., Trebeden H., Jaffray P., et al. Detoxification of reactive oxygen species by a nonpeptidyl mimic of superoxide dismutase cures acetaminophen-induced acute liver failure in the mouse. Hepatology 2001, 33:1173-1180.
71. Lores Arnaiz S., Llesuy S., Cutrin J.C., Boveris A. Oxidative stress by acute acetaminophen administration in mouse liver. Free Radical Biology and Medicine 1995, 19:303-310.
72. Hinson J.A., Pohl L.R., Monks T.J., Gillette J.R. Acetaminophen-induced hepatotoxicity. Life Sciences 1981, 29:107-116.
73. Hinson J.A., Roberts D.W., Benson R.W., Dalhoff K., Loft S., Poulsen H.E. Mechanism of paracetamol toxicity. Lancet 1990, 335:732.
74. Harvison P.J., Guengerich F.P., Rashed M.S., Nelson S.D. Cytochrome P-450 isozyme selectivity in the oxidation of acetaminophen. Chemical Research in Toxicology 1988, 1:47-52.
75. Moldeus P. Paracetamol metabolism and toxicity in isolated hepatocytes from rat and mouse. Biochemical Pharmacology 1978, 27:2859-2863.
76. David Josephy P. The molecular toxicology of acetaminophen. Drug Metabolism Reviews 2005, 37:581-594.
77. Larson A.M. Acetaminophen hepatotoxicity. Clinics in Liver Disease 2007, 11:525-548. [vi].
78. Lleo A., Invernizzi P., Mackay I.R., Prince H., Zhong R.Q., Gershwin M.E. Etiopathogenesis of primary biliary cirrhosis. World Journal of Gastroenterology: WJG 2008, 14:3328-3337.
79. Lleo A., Selmi C., Invernizzi P., Podda M., Coppel R.L., Mackay I.R., et al. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology 2009, 49:871-879.
80. Lleo A., Bowlus C.L., Yang G.X., Invernizzi P., Podda M., Van de Water J., et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 2010, 52:987-998.